Axitinib

115 interactions 351 cited references
Also sold as: Inlyta Inlyta®
About Axitinib

Axitinib is used alone to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in people who have not been treated successfully with another medication. Axitinib is used in combination with avelumab (Bavencio) or pembrolizumab (Keytruda) to treat advanced renal cell carcin… Read the full Axitinib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Bacillus Of Calmette And Guerin Vaccine, Live Smallpox Monkeypox Vaccine Typhoid Vaccine Varicella Virus Vaccine, Live Yellow Fever Vaccine
12 Contraindicated 97 Major 6 Moderate
All (115) Contraindicated (12) Major (97) Moderate (6)

Contraindicated

Axitinib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Axitinib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Axitinib Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Axitinib Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Axitinib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Axitinib Mifepristone Korlym Increased CYP3A4 substrate with NTI exposure Details Axitinib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Axitinib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Axitinib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Axitinib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Axitinib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Axitinib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Axitinib Abametapir Increased exposure of CYP3A4 substrate Details Axitinib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Axitinib Belumosudil Rezurock Increased OATP1B1 substrate exposure Details Axitinib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Axitinib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Axitinib Apalutamide Erleada Reduced OATP1B1/CYP3A4 substrate exposure Details Axitinib Atazanavir Reyataz Increased axitinib plasma concentrations Details Axitinib Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Axitinib Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Axitinib Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Axitinib Boceprevir Increased axitinib plasma concentrations Details Axitinib Bosentan Reduced axitinib exposure Details Axitinib Carbamazepine Carbatrol Reduced axitinib exposure Details Axitinib Ceritinib Zykadia Increased exposure of CYP3A substrate Details Axitinib Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Axitinib Clarithromycin Biaxin Increased axitinib exposure Details Axitinib Conivaptan Vaprisol Increased CYP3A substrate exposure Details Axitinib Crizotinib Xalkori Increased exposure of the CYP3A substrate Details Axitinib Daridorexant Increased CYP3A4 substrate with NTI exposure Details Axitinib Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Axitinib Ebola Zaire Vaccine, Live An increased risk of infection by the live vaccine Details Axitinib Efavirenz Reduced axitinib exposure Details Axitinib Elexacaftor Increased OATP1B1 substrate exposure Details Axitinib Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Axitinib Eltrombopag Alvaiz Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Axitinib Enasidenib Idhifa Altered (increased/reduced) axitinib exposure and an increased risk of axitinib-related adverse effects or reduced efficacy of axi... Details Axitinib Enzalutamide Xtandi Reduced axitinib exposure Details Axitinib Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.